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Abstract
Management of patients with hepatic metastases as 
the sole metastatic site at diagnosis of gastric cancer 
(synchronous setting) or detected during follow-up 
(metachronous) is controversial. The prevailing attitude in 
these cases is passive, leading to surgical palliation and, 
possibly, to chemotherapy. Authors focused this editorial 
in order to promote a more pragmatic attitude. They 
stress the importance of recognizing the good candidates 
to curative surgery of both gastric cancer and hepatic 
metastases (synchronous setting) or hepatic disease 
alone (metachronous disease) from those who will not 
benefit from surgical therapy. In fact, in adequately 
selected subgroup of patients surgery, especially if 
integrated in multimodal therapeutic strategies, may 
achieve unexpected 5-year survival rates, ranging 
from 10% to 40%. The critical revision of the literature 
suggests that some simple clinical criteria exist that may 
be effectively employed in patients selection. These are 
mainly related to the gastric cancer (factors T, N, G) and 
to the extent of hepatic involvement (factor H). Upon 
these criteria it is possible to adequately select about 
50% of cases. In the remaining 50% of cases a critical 
discussion on a case-by-case basis is recommended, 
considering that among these patients some potential 
long-survivors exist, that survival is strictly influenced 
by the ablation of the tumor bulk and by multimodality 
treatments including chemotherapy and that in expert 
institutions this kind of surgery is performed with very 
low mortality and morbidity rates.
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master difficult techniques, face perilous postoperative 
complications and accept surgical mortality for similar 
but often worse results. Why is this not the case for 
gastric cancer with hepatic metastases as the only 
metastatic site?
The main reason may be found in the curve 
that describes survival after surgery: a step drop is 
systematically observed during the first year, mortality 
is around 40% after 6 mo and reaches 70%-80% 1 
year after surgery. This suggests the critical point: 
selection of candidates to curative surgery. All papers 
published on this topic investigate selection criteria and 
prognostic factors of major clinical relevance. However, 
thirteen of them[5-16] are of great interest since their 
results are based on cohorts of patients as observed in 
every-day clinical practice and not upon super-selected 
populations submitted to surgical treatment. 
In the different settings of the disease, syn-
chronous and metachronous presentation, simple 
clinical variables such as factor T of gastric primary 
and extension H of hepatic involvement may be 
employed to select the best candidates for curative 
surgery[6,7,10,15,16] and those to be excluded from 
hepatic resection. These factors also seem to display a 
cumulative effect. In the synchronous setting[6] gastric 
cancer T > 2 and scattered bilobar metastases (H3) 
are negative prognostic factors with clear clinical value. 
In fact, median and 5-year survival was respectively 
23 months and 27% for the 10% of cases which did 
not display the 2 risk factors, while patients affected 
by T ≥ 3 gastric cancer and H3 metastases (30% of 
cases) displayed a median survival of 6 months and 
did not survive more than 16 months. Accordingly, 
in the metachronous setting[10] the variable T4, N+ 
and G3 showed a negative prognostic role. Patients 
not presenting these variables (7%) had a 5-year 
survival rate of 40%, those affected by two or three 
negative prognostic factors (48%) had a median 
survival of 4 ± 3 mo. Upon these bases, it is possible 
to select the best candidates for curative resection, 
those for whom an aggressive treatment should be 
mandatory, from those who will not benefit from 
hepatectomy. All together, they represent 40%-55% 
of cases. In the middle one finds the huge group of 
cases presenting 1 risk factor. They do not display an 
astonishing survival performance (median survival is 
around 8-9 mo). Yet among these it is possible to find 
long-term survivors. We think that in these cases the 
therapeutic decision should be discussed on a case 
by case basis, considering that the major prognostic 
factor emerging from the cited papers is represented 
by the possibility to achieve a curative resection. This 
should be pursued whenever possible, also referring to 
ablative procedures such as RFA[5,8]. It must be noted 
that in tertiary Institutions these complex procedures 
are safe: in both the synchronous and metachronous 
setting mortality is limited to some unit percent 
(0%-3%) and morbidity reflects that of major surgery, 
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Core tip: Authors highlight the reasons for an active 
attitude in case of patients with gastric cancer and 
hepatic metastases. They show that when the liver is 
the sole metastatic site it is possible to select the good 
candidates for surgical management of both gastric 
cancer and hepatic metastases and to recognize those 
who will not benefit from an aggressive attitude. They 
also show that the multidisciplinary approach to these 
patients is the best option.
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Sparkling is research and clinical activity which focuses 
on hepatic metastases from colorectal cancer, but the 
waters surrounding hepatic metastases from gastric 
cancer are still. 
In 2005 the French Association of Surgery[1] 
produced the first report with more than 100 
hepatectomies, recruiting 101 cases from 41 centres. 
In 2010 Kerkar et al[2] reviewed 436 patients collected 
from 19 surgical series published over a 20-year time-
span. The most recent review, published by Fitzgerald 
et al[3] collected 481 cases published in the period 
1990-2013. Despite this, the incidence of hepatic 
metastasis from gastric cancer during the course of 
the disease figures around 20% in eastern countries 
such as Japan and South Korea and rises to 30%-40% 
in Europe and North America, lying unmeasured -yet 
probably over 50%- in other less closely-monitored 
countries.
It seems that the clinical community does not 
include surgery among the therapeutic options for 
these patients. We all have daily experience of the 
aggressive biology of gastric cancer, especially when 
at metastatic stage. We also experience the frequent 
coexistence of multiple metastatic sites as well as 
hepatic involvement and are also aware that hepatic 
and systemic recurrence is almost systematically 
observed after hepatectomy or ablative treatments. 
However, literature is consistent in reporting un-
expected results after aggressive multidisciplinary 
management including surgery in gastric cancer 
patients when the liver is the sole metastatic site[4]. 
This clinical context is observed in about 33% of cases 
presenting hepatic metastases, but in these cases 
5-year survival rate is reported between 10% and 
40% of cases.
In other fields of our work, such as pancreatic 
cancer, surgeons struggle in their theatres for hours, 
well under 20% of cases. 
We would like to stress here that the completeness 
of tumor bulk removal is a key-point of the therapeutic 
strategy. The expansion of the experience and the most 
recent series focusing on surgical subgroups[1,17-25], 
indicate this point precisely. The importance of a 
radical resection/ablation of gastric cancer and hepatic 
metastases stands out progressively while other 
prognostic factors reveal themselves as disturbing and 
non-existent[4].
A pragmatic multi-disciplinary approach, integrating 
neo-adjuvant and/or adjuvant chemotherapy, offers 
the possibility for further improvements in results. In 
our recent paper[10], adjuvant chemotherapy revealed 
itself as the most powerful prognostic factor. The 
effective integration of the different disciplines will be 
the next breakthrough although it will require a great 
deal of hard work. Though a paradox, chemotherapy 
with neo-adjuvant intent is not routinely accepted 
in metastatic settings, especially in synchronous 
presentation, and patients are more often enrolled in 
protocols of palliative chemotherapy.
Concluding this editorial, we repeat that through 
slow but constant progress it is possible today to 
operate a certain selection of candidates to curative 
resection and that complete removal of the neoplastic 
bulk must be achieved. It is relatively easy to recognize 
the best candidates to be operated on or - at least - to 
be centralized in expert centres, where these complex 
procedures can be performed with very low operative 
morbidity and mortality. Upon this basis, we hope 
that a μετάνοια (change of mind) will spread through 
our community, leading to a general and consistent 
improvement of survival results, at least for some of 
the most unlucky among gastric cancer patients. 
Will we accept the challenge?
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